SCHEMBL1444722

SCHEMBL1444722

NC1(CO)CCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL14311830 0.98 SLC6A2 (0.33)
SCHEMBL1444960 0.86
SCHEMBL782327 0.84
SCHEMBL17754732 0.84
SCHEMBL22469853 0.84 SLC6A2 (0.36)
Hydrochloric Acid SCHEMBL22469308 0.82 SLC6A2 (0.36)
Hydrochloric Acid SCHEMBL1991419 0.82 SLC6A2 (0.32)
Hydrochloric Acid SCHEMBL3209364 0.82 SLC6A2 (0.32)
SCHEMBL1485534 0.78
Tert-Butyl Formate SCHEMBL28680027 0.78 TDP1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0326916-A2 Quinolone- and naphthyridone-carboxylic acid derivatives, method for their preparation and antibacterial agents and food additives containing them BAYER AG (DE) 1989-08-09 EP claimed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed
US-11059784-B2 Oxime ether compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-13 US disclosed
US-20210147361-A1 OXIME ETHER COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-05-20 US disclosed
US-20210147361-A1 OXIME ETHER COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-05-20 US disclosed
EP-3507278-B1 SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-01-27 EP disclosed
EP-3507278-B1 SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-01-27 EP disclosed
US-10633354-B2 Substituted tricyclic heterocyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2020-04-28 US disclosed
US-10633354-B2 Substituted tricyclic heterocyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2020-04-28 US disclosed
CN-1035945-C 5-Alkylquinolonecarboxylic acids BAYER AG (DE) 1997-09-24 CN disclosed
EP-0677522-A1 8-METHOXYQUINOLONECARBOXYLIC ACID DERIVATIVE YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1995-10-18 EP disclosed
US-5453422-A Animal growth promoters BAYER AKTIENGESELLSCHAFT (DE) 1995-09-26 US disclosed
US-5284842-A Active against gramnegative bacteria BAYER AKTIENGESELLSCHAFT (DE) 1994-02-08 US disclosed
US-5252734-A Antibacterial 5-alkylquinolonecarboxylic acids BAYER AKTIENGESELLSCHAFT (DE) 1993-10-12 US disclosed
US-5173484-A Animal growth regulators BAYER AKTIENGESELLSCHAFT (DE) 1992-12-22 US disclosed
US-5140033-A For prevention or treatment of bacterial infections in humans or animals BAYER AKTIENGESELLSCHAFT (DE) 1992-08-18 US disclosed
CN-1046162-A The 5-Alkylquinolonecarboxacids acids BAYER AG (DE) 1990-10-17 CN disclosed
EP-0391132-A1 5-Alkylquinolinone carboxylic acids BAYER AG (DE) 1990-10-10 EP disclosed
EP-0326916-A2 Quinolone- and naphthyridone-carboxylic acid derivatives, method for their preparation and antibacterial agents and food additives containing them BAYER AG (DE) 1989-08-09 EP disclosed